Nanjing IASO Biotechnology Co., Ltd. (IASO Bio) made its debut at the 6th China International Import Expo (CIIE) with FUCASO, the world’s first fully-human CAR-T, and entered into a strategic partnership with several international medical institutions, bringing hope for cure to…
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled…
OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the recommendation of the study’s Independent Data Monitoring…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for the detection of hepatitis E virus (HEV) infections in countries accepting the CE mark. By testing for HEV infection, clinicians…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company received the Best IR Award, the Greatest IR Improvement Premium Companies, and the Best Continual IR Efforts Premium Companies at the 2023 IR Award hosted by the Japan Investor Relations Association (JIRA), the…
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today presented first-in-human data from a Phase 1 trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with…
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) received…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated…
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics, announced new findings that its blood biomarkers Aβ42/Aβ40 (amyloid-beta) and…
Marinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY® (ganaxolona) –Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), uma empresa farmacêutica especializada no desenvolvimento de terapêuticas inovadoras para tratar distúrbios convulsivos, anunciou hoje o início do Marinus Access Program…
Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral…
